Literature DB >> 23862710

Standardized workflows for increasing efficiency and productivity in discovery stage bioanalysis.

Kevin P Bateman1, Lucinda Cohen, Bart Emary, Vincenzo Pucci.   

Abstract

Merck consolidated discovery stage bioanalytical functions into the Department of Pharmacokinetics, Pharmacodynamics & Drug Metabolism in 2007. Since then procedures and equipment used to provide important quantitative data to project teams have been harmonized and in many cases standardized. This approach has enabled movement of work across the network of laboratories and has resulted in a lean, flexible and efficient organization. The overall goal was to reduce time and resources spent on routine activities while creating time to perform research in new areas and technologies to support future scientific needs. The current state of discovery bioanalysis at Merck is discussed, including hardware and software platforms, workflow procedures and performance metrics. Examples of improved processes will be discussed for compound tuning, LC method development, analytical acceptance criteria, automated sample preparation, sample analysis platforms, data processing and data reporting.

Entities:  

Mesh:

Year:  2013        PMID: 23862710     DOI: 10.4155/bio.13.162

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  2 in total

1.  In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385.

Authors:  Jin-Ju Byeon; Min-Ho Park; Seok-Ho Shin; Yuri Park; Byeong Ill Lee; Jang-Mi Choi; Nahye Kim; Seo-Jin Park; Min-Jae Park; Jeong-Hyeon Lim; Young-Guk Na; Young G Shin
Journal:  Molecules       Date:  2020-03-02       Impact factor: 4.411

2.  Quantitative Analysis of Daporinad (FK866) and Its In Vitro and In Vivo Metabolite Identification Using Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry.

Authors:  Minjae Park; Byeong Ill Lee; Jangmi Choi; Yuri Park; Seo-Jin Park; Jeong-Hyeon Lim; Jiyu Lee; Young G Shin
Journal:  Molecules       Date:  2022-03-21       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.